Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Michelle N RheaultCharles E AlpersJonathan BarrattStewart BielerPietro A CanettaDong-Wan ChaeGaia CoppockUlysses DivaLoreto GesualdoHiddo J L HeerspinkJula K InrigGianna M KirsztajnDonald KohanRadko KomersLaura A KooiengaKenneth LiebermanAlex MercerIrene L NoronhaVlado PerkovicJai RadhakrishnanWilliam RoteBrad RovinVladimir TesarHernán TrimarchiJames TumlinMuh Geot WongHoward Trachtmannull nullPublished in: The New England journal of medicine (2023)
Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan. (Funded by Travere Therapeutics; DUPLEX ClinicalTrials.gov number, NCT03493685.).